J-Pharma Co.,Ltd.
|
| Code |
Sector |
Market |
Lead Underwriter |
Date of listing approval |
IPO Date |
| 520A |
Pharmaceuticals |
Growth |
SBI SECURITIES Co.,Ltd. |
2026/02/19 |
2026/03/25 |
| 【Description】 |
| |
IPO Information |
| Opening Price |
Y809 |
Total Amount |
Y3,278,880,000 |
| IPO Price |
Y880 |
--Company |
Y2,623,104,000 |
Aggregate Value
(based on Initial Price) |
14,424
(Unit:1 million) |
--Leading Shareholder |
Y393,465,600 |
| Listed Shares(total) |
3,726,000 |
--Lead Manager |
Y262,310,400 |
| Trading Unit |
100 |
|
Offering Price PER
(based on previous period) |
-4.78 |
Offering Price PBR
(based on previous period) |
-1.20 |
| Initial Price PER |
-4.40 |
Initial Price PBR |
-1.10 |
| New Shares |
3,240,000 |
Existing Shares |
486,000（only O.A.） |
| Shares Outstanding |
Pre IPO |
14,589,610.00 |
PostIPO |
17,829,610.00 |
| Paid Up Capital |
PreIPO |
Y682,700,000 |
PostIPO |
Y1,606,939,360 |
| Use of Funds Raised |
|
Financial Data |
| Units:Y1,000 |
| Fiscal Year End |
|
Revenue |
Current Profit |
Net Profit |
Net Assets |
| 2023/03 |
Consolidated |
- |
- |
- |
- |
| Non-consolidated |
- |
-1,086,760 |
-1,098,260 |
1,407,818 |
| 2024/03 |
Consolidated |
- |
- |
- |
- |
| Non-consolidated |
- |
-1,640,255 |
-1,652,337 |
950,122 |
| 2025/03 |
Consolidated |
- |
- |
- |
- |
| Non-consolidated |
- |
-1,527,089 |
-1,499,008 |
2,377,869 |
Recent Quarter
2025/12 |
Consolidated |
- |
- |
- |
- |
| Non-consolidated |
- |
-2,047,444 |
-1,876,851 |
2,344,635 |
| Per Share |
Units:Y1 |
| Fiscal Year End |
|
Dividend |
Net Earning |
Equity |
|
| 2023/03 |
Consolidated |
0.00 |
- |
- |
|
| Non-consolidated |
-190.55 |
-789.60 |
|
| 2024/03 |
Consolidated |
0.00 |
- |
- |
|
| Non-consolidated |
-263.57 |
-926.67 |
|
| 2025/03 |
Consolidated |
0.00 |
- |
- |
|
| Non-consolidated |
-184.05 |
-734.62 |
|
| Fiscal Year End |
|
Dividend |
Net Earning |
Equity |
|
Recent Quarter
2025/12 |
Consolidated |
|
- |
- |
|
| Non-consolidated |
-157.57 |
- |
|
Comment |
| ■Over allotment (486,000) |
| Consolidated Subsidiaries |
| Name |
Address |
| Underwriters |
| Allocation |
Underwriter |
Tel |
| 90% |
SBI SECURITIES Co.,Ltd. |
03-5562-7210 |
| 5% |
Daiwa Securities Co. Ltd |
03-5555-2111 |
| 1% |
Tokai Tokyo Securities Co., Ltd |
03-3566-8811 |
| 1% |
TOYO SECURITIES CO.,LTD |
03-5117-1040 |
| 1% |
Matsui Securities Co., Ltd |
03-5216-0606 |
| 1% |
Monex, Inc |
03-4323-3800 |
| 1% |
Rakuten Securities Holdings, Inc. |
03-6406-2681 |
| Data |
| Date of incorporation |
2005/12/26 |
| Company address |
Tokyo 105-0013 |
| Telephone |
03-6432-4270 |
| President |
|
| Homepage |
https://www.j-pharma.com/ |
| Auditor |
GINGA Audit |
|
|
| Major Shareholders |
| Shareholder Name |
Ratio |
| |
12.82% |
| |
12.30% |
| |
7.77% |
| |
5.55% |
| |
3.96% |
| |
3.80% |
| |
3.34% |
| |
3.07% |
| |
2.93% |
| |
2.79% |
| Number of Employees |
16 as of 2026/01/31 |
| Birth Date of Representative |
1959/02/03 |
|
|
IPO最新情報、セミナー・イベント情報などをタイムリーにお届けします。
|
|
IPO関連ニュースをX（旧Twitter）でも掲載中。初値予想アンケートも実施中です！
|
|
今後の躍進が期待される注目銘柄のアナリストレポートをご覧いただけます。
|
|
個人投資家向けIRセミナーを開催しませんか？開催希望企業募集中！
|
|
